Earnings Call Intelligence Subscribe
Home › Call Sheets › IDXX › Q4'25
Call sheet · Q4'25

IDEXX Laboratories (IDXX)

Q4'25 earnings call · held February 2, 2026 · compared with the Q3'25 call · management-credibility review
11/12
Disclosure score
-
Financial quality
Bottom line
The sleeper story is InVue DX transforming from placement revenue to consumables engine-$75M in 2025 instrument revenue will become recurring consumables flywheel with 6,400 units generating $3,500-$5,500 each annually. While everyone focuses on visit headwinds, the real story is diagnostic frequency expansion and aging pet demographics creating structural tailwinds. International hitting 12% growth just as commercial investment cycle ends sets up margin leverage in 2026. Jay's quote captures it: 'Early signs of aging pet population...solid visit growth for canines five-plus years old'-pandemic puppy demographics are flipping favorable. The binding constraint isn't demand, it's their ability to scale consumables production to meet InVue utilization ramp. My view changes if InVue utilization per analyzer disappoints the $3,500-$5,500 range or if international growth decelerates below double-digits despite the commercial investments.

The 30-second version

  • InVue DX is becoming the consumables growth engine everyone's missing
  • Visit decline stability masks diagnostic frequency expansion-sector headwinds becoming tailwinds
  • International acceleration to 12% organic growth sets up margin expansion story

What changed this quarter

MetricQ3'25Q4'25Change
Total Revenue$1.08B (+9% YoY)$1.19B (+14% YoY)+500 bps acceleration
CAG Diagnostics Recurring Revenue$834M (+10% organic)$915M (+10% organic)Sustained double-digit despite visit pressures
US CAG Diagnostics Recurring~$550M (+8% organic)~$600M (+9% organic)+100 bps acceleration
International CAG Diagnostics Recurring~$284M (+14% organic)~$315M (+12% organic)-200 bps deceleration but still double-digit
VetLab Consumables RevenueNot disclosed (+16% organic)Not disclosed (+15% organic)-100 bps but still mid-teens
CAG Instrument Revenue+71% organic+69% organicMinor deceleration, still exceptional
Operating Margin32.4% (+120 bps YoY)31.6% (+90 bps YoY)-30 bps margin decline quarter-over-quarter
EPS$3.40 (+15% YoY)$3.08 (+17% YoY)+200 bps EPS growth acceleration
Premium Instrument Placements5,665 (+37% YoY)6,567 (+42% YoY)+500 bps placement acceleration
InVue DX Placements1,753 in Q31,900 in Q4+147 unit sequential increase

Accountability tracked

8 new promises made5 narrative shifts flagged8 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full IDXX Q4'25 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.